Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVA1309
- Development stage
- Preclinical
- Lead developer
- Novassay
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NVA1309 is a small molecule ligand developed by Novassay that targets the **α2δ-1** and **α2δ-2** subunits of voltage-gated calcium channels (VGCCs). It is currently in preclinical development (GLP toxicology stage) for the treatment of various chronic neuropathic pain conditions. By binding to these specific subunits, NVA1309 is designed to modulate the trafficking and functional activity of calcium channels, thereby reducing the hyperexcitability of neurons and the release of excitatory neurotransmitters associated with chronic pain states. The drug is being investigated for multiple indications, including diabetic painful neuropathic pain (DPNP), post-surgical pain (PSP), post-herpetic neuralgia (PHN), lumbar radiculopathy (sciatica), and fibromyalgia.
- Other names
- NVA1309NVA-1309NVA 1309
02
Targets
CACNA2D2 (Voltage-gated calcium channel subunit alpha-2/delta-2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on NVA1309.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVA1309.